has set although the company went through the situation of COVID-19. The company is also considered to be able to adjust the work process to be able to operate in accordance with the goals set. Cost of
therefore it is appropriate to adjust impairment items of the said assets in this quarter to be in line with trading prices set in purchase agreement EXPENSES % per % per % per % per Revenue Revenue % Revenue
that investors are fully informed, prior to making investment decisions, of the fact that the company will not adjust the exercise ratio or the exercise price upon the occurrence of such events. Clause
sector as mentioned above, the SEC will also have to adjust its role as a regulator, in terms of regulatory regime and work procedures. On the market supervision front, the private sector and market
Administration (CFDA) at the beginning of 2 0 1 8 as the Company had to redesign its packaging to comply with the requirements of the license. Furthermore, the Company also found it necessary to adjust its sales
year to be in parallel with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and did not fully mirror the slowdown in revenue as there is a lead time for
ongoing outbreak of COVID–19, forcing many customers to adjust their working method which have an effect on the operation and delivery of the Company's projects that cause the operation to be delayed than
reducing production cost and also negotiating with customers to review and adjust selling price every quarter. 2.2. Distribution costs for 2018 was in the amount of 4.95 million baht, increased by 1.16
with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and did not fully mirror the slowdown in revenue as there is a lead time for certain expenses that the
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change